Press Releases
- Apr 3, 2025Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral LeukoplakiaRead More
- Apr 2, 2025Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in DogsRead More
- Feb 20, 2025Orocidin and Syngene Partner to Accelerate Biotech InnovationRead More
- Feb 18, 2025Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity StudyRead More
- Feb 3, 2025Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia Read More
- Jan 28, 2025Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis TreatmentRead More
- Jan 14, 2025Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin’s Breakthrough Treatment for PeriodontitisRead More
- Dec 17, 2024Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025Read More
- Dec 10, 2024NORDICUS now trading under symbol NORDRead More
- Nov 12, 2024Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/SRead More